Last reviewed · How we verify
Estrofem
At a glance
| Generic name | Estrofem |
|---|---|
| Also known as | Progynova, Estrsdiol |
| Sponsor | Assaf-Harofeh Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
- Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study (NA)
- Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome (PHASE4)
- Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome (PHASE4)
- Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy (PHASE3)
- Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test (NA)
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders (PHASE4)
- The Temporo-spatial Dynamics of Genital Tract Microbiota
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estrofem CI brief — competitive landscape report
- Estrofem updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI